ArticleTissue engineering. Part A2012
Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate for muscle tissue engineering.
Article in Tissue engineering. Part A, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00070811 (Functional Outcomes of Cleft Lip and Lip Revision Surgery), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Functional Outcomes of Cleft Lip and Lip Revision Surgery
Who cites it
16 citing papers in PubMed.
- Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.Stem cell research & therapy · 2025Review
- Sources, Characteristics, and Therapeutic Applications of Mesenchymal Cells in Tissue Engineering.Tissue engineering and regenerative medicine · 2022Review
- Milestones and current achievements in development of multifunctional bioscaffolds for medical application.Bioactive materials · 2021Review
- Alginate Microencapsulation for Three-Dimensional In Vitro Cell Culture.ACS biomaterials science & engineering · 2021Review
- Materials-Directed Differentiation of Mesenchymal Stem Cells for Tissue Engineering and Regeneration.ACS biomaterials science & engineering · 2018Article
- The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models.Frontiers in physiology · 2018Review
- 3D brown adipogenesis to create "Brown-Fat-in-Microstrands".Biomaterials · 2016Article
- Chondrogenic induction of mesenchymal stromal/stem cells from Wharton's jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering.Stem cell research & therapy · 2015Article
- Opportunities and challenges in three-dimensional brown adipogenesis of stem cells.Biotechnology advances · 2015Review
- Calcium phosphate scaffolds combined with bone morphogenetic proteins or mesenchymal stem cells in bone tissue engineering.Chinese medical journal · 2015Review
- Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement.Acta biomaterialia · 2014Article
- Osteogenic differentiation of human mesenchymal stem cells through alginate-graft-poly(ethylene glycol) microsphere-mediated intracellular growth factor delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering.Biomaterials · 2013Article
- Alginate-Based Biomaterials for Regenerative Medicine Applications.Materials (Basel, Switzerland) · 2013Review
- Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.Recent patents on regenerative medicine · 2013Article
- Human umbilical cord stem cell encapsulation in novel macroporous and injectable fibrin for muscle tissue engineering.Acta biomaterialia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Human umbilical cord mesenchymal stem cells (hUCMSCs) are inexhaustible and can be obtained without an invasive surgery. To date, there has been no report on seeding hUCMSCs in three-dimensional scaffolds for muscle tissue engineering. The objectives of this study were to (1) investigate hUCMSC seeding in a scaffold for muscle engineering and (2) develop a novel construct consisting of hUCMSC-encapsulating and fast-degradable microbeads inside a hydrogel matrix. The rationale was that the hydrogel matrix would maintain the defect volume, while the microbeads would degrade to release the cells and concomitantly create macropores in the matrix. hUCMSCs were encapsulated in alginate-fibrin microbeads, which were packed in an Arg-Gly-Asp (RGD)-modified alginate matrix (AM). This construct is referred to as hUCMSC-microbead-AM. The control consisted of the usual cell encapsulation in AM without microbeads (referred to as hUCMSC-AM). In the hUCMSC-AM construct, the hUCMSCs showed as round dots with no spreading at 1-14 days. In contrast, cells in the hUCMSC-microbead-AM construct had a healthy spreading and elongated morphology. The microbeads successfully degraded and released the cells at 8 days. Myogenic expressions for hUCMSC-microbead-AM were more than threefold those of hUCMSC-AM (p<0.05). Immunofluorescence for myogenic markers was much stronger for hUCMSC-microbead-AM than hUCMSC-AM. Muscle creatine kinase of hUCMSC-microbead-AM at 14 days was twofold that of hUCMSC-AM (p<0.05). In conclusion, hUCMSC encapsulation in novel fast-degradable microbeads inside a hydrogel matrix was investigated for muscle engineering. Compared to the usual method of seeding cells in a hydrogel matrix, hUCMSC-microbead-AM construct had greatly improved cell viability and myogenic differentiation, and hence, is promising to enhance muscle regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.